News

DEAR MISS MANNERS: I am a gentleman who strives to live a mannerly life. In that regard, when riding public transportation, I ...
There's a clear downside to the Norwegian policy that encourages allowing elderly people to live at home for as long as ...
An elderly couple who hired a contractor to renovate their roof claims they were scammed out of tens of thousands of dollars, ...
Maria Pasqual was a flower farmer in Maili, loved by those who encountered her. The family who lives next door to her farm ...
A missing elderly woman with dementia has been found deceased in Daviess County. Lola Davis, 89, of Mt. Vernon, Indiana, went ...
Friends and neighbors are remembering the elderly woman who lost her life in this weekend’s fire in Maili as a kind soul who ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
The suspect told the victim to “shut up,'' sparking a dispute in which she became "aggressive'' and he walloped her multiple ...
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.
The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
BofA raised the firm’s price target on KalVista (KALV) to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of hereditary ...